Key Drivers
- Stronger Liquidity
- Debt Reduction
- Cash Flow Risk
AIAI Summary
Zevra is now a cash-generative commercial rare-disease company, but the investment case hinges on whether U.S. MIPLYFFA can sustain profitable patient expansion despite single-product concentration, while Europe and celiprolol remain upside—not base-case—value drivers.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Stronger Liquidity
- •Debt Reduction
- •Cash Flow Risk
ZVRA's liquidity, leverage, and near-term cash generation improved sharply, but negative retained earnings and weak 2025 cash conversion warrant caution despite attractive reported valuation multiples.
Price Behavior
Key Price Behavior Insights:
- •Weakening momentum
- •Key support
- •Breakout needed
ZVRA was range-bound but weakening last month, with $11.55–$11.65 support critical and a breakout above $12.68 needed for bullish confirmation.
Sharp rebound from $9.51 in late
Sentiment & News
Key News Insights:
- •Investor Outreach
- •Long-Term Data
- •Employee Grants
Zevra Therapeutics is boosting investor visibility while strengthening MIPLYFFA's long-term clinical evidence and expanding its workforce.
The updates are moderately positive for Zevra, supporting credibility in its rare-disease pipeline and investor engagement
Similar Companies in Healthcare
Other companies in the same sector with AI ratings